Identifying new immunotherapeutic targets for endocrine autoimmunity
Active Cooperative Agreement Awarded Last action
- Award ID
- U19AI181729
- Recipient
-
University Of California, LOS Angeles UEI RN64EPNH8JC6
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,846,492
Award facts
- Assistance listing
- 93.310 Trans-NIH Research Support
- Completion date 44% complete
- Funding agency
- Office of the Director National Institutes of Health, Department of Health and Human Services
- Place of performance
- Los Angeles, CA 90095, USA
Award details come from USAspending.gov.
Description
- Abstract
- (overall) autoimmune endocrinopathies include a number of conditions in which the immune system destroys healthy hormone-producing tissues. These conditions affect a large number of americans, many of them female, but have not yet been the focus of ACE studies in the past. Moreover, unlike most other autoimmune conditions, autoimmune endocrinopathies are not usually treated with immunotherapies, despite clear evidence that their etiology is immune-mediated. Thus, there is an urgent need to better understand autoimmune pathogenesis to identify targets for immunotherapies in these conditions. This new ACE proposal seeks to delineate mechanisms of autoimmune chronicity as critical pathways in the establishment of autoimmune endocrinopathies. The principal project delineates the epigenetic and transcriptional mechanisms underlying chronicity in autoimmune endocrinopathies. These studies will determine whether an epigenetic regulator UTX may a role in conversion of stem-like progenitor CD8+ t cells to effectors in autoimmune endocrinopathies. The collaborative project addresses spatial and temporal determinants of immune chronicity in cancer immunotherapy-related immune related adverse events (iraes). Endocrine iraes of great interest given the large proportion of cancer patients who now receive immunotherapies and develop these unwanted side effects. Finally, many autoimmune endocrinopathies are SEX-biased, and the pilot project addresses sexual dimorphism in immune chronicity pathways. In particular, UTX is an x-linked gene that is differentially expressed in male VS. Female CD8+ t cells, and we will explore UTX's role in mediating SEX differences in progenitor to effector conversion. Our ACE includes an administrative core, which will ensure efficient day-to-day operational support; an ACE funds management core, which will administer financial and consortium agreements; and an ACE biorepository core, which takes advantage of the well-developed biorepository infrastructure system in place at ucla. Our program will build a cohesive and multi-disciplinary team of immunologists, clinicians, and computational biologists to contribute our deep expertise to the ACE collaborative enterprise.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $250,000 | |
| Amendment | $619,900 | |
| Amendment | $619,900 | |
| Amendment | $737,346 | |
| Original award | $619,346 |
Quick answers
Who received award U19AI181729?
U19AI181729 was awarded to University Of California, LOS Angeles by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 10, 2024.
How much is award U19AI181729 worth?
$2,846,492 has been obligated on U19AI181729.
Which agency awarded U19AI181729?
National Institute of Allergy and Infectious Diseases (National Institutes of Health) awarded U19AI181729, with funding from Office of the Director (National Institutes of Health).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award